The purpose of this study is to establish differences in the primary outcome of walking dysfunction using the 12-Item Multiple Sclerosis Walking Scale (MSWS-12) and to establish differences in the secondary outcome of HRQoL using the 29-Item Multiple Sclerosis Walking Scale (MSWS-29) between the exercise training intervention condition and the waitlist control condition following the 16-week intervention period.
diagnosis of MS
relapse-free in the past 30 days
self-identify as Hispanic/Latino
Patient Determined Disease Steps Scale (PDDS) score between 3.0 (gait disability) and 6.0 (bilateral support) indicates walking disability.
significant exercise-related risk factors or contraindications, assessed individually using the Physical Activity Readiness Questionnaire (PAR-Q; requires clearance from physician).
Parallel
Exercise Training
BehavioralParticipants will then be mailed exercise materials in their preferred language, including the program manual, logbook, calendar, newsletters, Fitbit, and resistance bands, along with instructions for telephone or video conference calls. This is a 16-week, home-based program, supported remotely via Internet-based behavioral coaching, which integrates behavior change techniques based on Social Cognitive Theory (SCT)
Change in walking ability as assessed by the 12-Item Multiple Sclerosis Walking Scale (MSWS-12)
This is a 12 item questionnaire and each is scored on a 5-point Likert scale from 1(not at all) to 5(extremely). Total raw scores ranging from 12-60 are converted into standardized scores from 0-100, with higher scores indicating greater perceived walking impairment related to multiple sclerosis.
Change in HRQoL as assessed by the 29-Item Multiple Sclerosis Walking Scale (MSWS-29)
This is a 29 item questionnaire and each is scored from 1( not at all) to 5(extremely) , with a Raw score range from 29 to 145. This is then converted into a standardized scale from 0 to 100, with higher scores indicating worse walking impairment and greater impact of multiple sclerosis on mobility.
Click on the lead sponsor to view all of their trials.
The University of Texas Health Science Center, Houston
Lead sponsor
National Institutes of Health (NIH)
Collaborator
